Articles From: EchoStar Reports Third Quarter 2014 Financial Results to Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma


ENGLEWOOD, Colo.
Sign-up for EchoStar Reports Third Quarter 2014 Financial Results investment picks
OLATHE, Kan., Nov.
Sign-up for Elecsys Corporation Divests RFID Assets investment picks
http://media.marketwire.com/attachments/201410/286630_MedytoxLogo420x102.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156997&ProfileId=051205&sourceType=1 NASHVILLE, TN --
Sign-up for Electronic Health Records Developer, Medical Mime, Launches System for Substance Abuse Treatment Centers investment picks
2014/11/6
SAO JOSE DOS CAMPOS, Brazil , Nov.
Sign-up for Embraer Announces Its Third Quarter 2014 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157031&ProfileId=051205&sourceType=1 NICOSIA, CYPRUS --
Sign-up for EMED Mining Public Limited ("EMED" or the "Company") Notification of a Change in Shareholding investment picks
ROCKVILLE, Md., Nov.
Sign-up for Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results investment picks
- GAAP EPS increases 35% to record $1.11 - Non-GAAP Economic EPS increases 15% to record $1.17 - Estimated Remaining Collections increase to record $5.1 billion - Encore deploys $336 million worldwide, $174 million in core U.S. market - Encore completes Atlantic Credit & Finance servicing platform and portfolio acquisition SAN DIEGO , Nov.
Sign-up for Encore Capital Group Announces Third Quarter 2014 Financial Results; Diversification Drives Record Quarter investment picks
2014/11/6
Encore Wire Corporation (NASDAQ Global Select: WIRE) announced today that Frank J.
Sign-up for Encore Wire Presenting at Southwest IDEAS Conference investment picks
IRVINE, Calif., Nov.
Sign-up for Endologix to Participate in Three Investor Conferences in November investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977543001&sourceType=1 http://www.ccnmatthews.com/logos/20110601-enerflex.jpg CALGARY, ALBERTA --
Sign-up for Enerflex Reports Third Quarter 2014 Financial Results and Announces an Increase to the Quarterly Dividend investment picks
– Company Posts Record Third Quarter Revenue of $329 Million – BOSTON, Nov.
Sign-up for EnerNOC Reports Results for Third Quarter of 2014 investment picks
HOUSTON, Nov.
Sign-up for ENGlobal Reports Third Quarter 2014 Results investment picks
EnLink Midstream Partners, LP (NYSE: ENLK) (the Partnership) today announced the pricing of $100.0 million aggregate principal amount of its 4.400% senior notes due 2024 (the “2024 Notes”) and $300.0 million aggregate principal amount of its 5.050% senior notes due 2045, at prices to the public of 104.007% and 99.452%, respectively, of their face value.
Sign-up for EnLink Midstream Announces Pricing of $400 Million of Senior Notes investment picks
EnLink Midstream Partners, LP (NYSE: ENLK) today announced its intention, subject to market conditions, to offer senior notes in a public offering.
Sign-up for EnLink Midstream Announces Public Offering of Senior Notes investment picks
- Third Quarter 2014 Net Revenue and Consolidated Adjusted EBITDA Increase 8% and 5% Respectively - - Free Cash Flow Increases 26% - - Establishes New Digital Media Segment - - Repurchases 0.8 Million Shares in the Third Quarter - SANTA MONICA, Calif.
Sign-up for Entravision Communications Corporation Reports Third Quarter 2014 Results investment picks
Envestnet (NYSE:ENV), a leading provider of unified wealth management technology and services to financial advisors, today reported financial results for its third quarter ended September 30, 2014.
Sign-up for Envestnet Reports Third Quarter 2014 Financial Results investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced third quarter 2014 operating and financial results and confirmed 2014 guidance.
Sign-up for Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the publication on the website of the American Society of Hematology (ASH) of an abstract entitled “The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia”. The abstract contains preliminary data from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The Company plans to present updated data from the trial at the 56 th annual meeting of ASH in San Francisco, Calif.
Sign-up for Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract investment picks
ATLANTA , Nov.
Sign-up for Equifax Board of Directors Declares Quarterly Dividend investment picks
ATLANTA , Nov.
Sign-up for Equifax To Present At SunTrust Conference investment picks
Erickson Incorporated (NASDAQ:EAC) (“Erickson,” the “Company,” “we,” “us” and “our”), a leading global provider of aviation services to a worldwide mix of commercial and government customers and the vertically integrated manufacturer and operator of the powerful, heavy-lift helicopter, the Erickson S-64 Aircrane, today announced third quarter and year to date 2014 financial results.
Sign-up for Erickson Reports Third Quarter 2014 Results investment picks
Eros International Plc (NYSE:EROS) (“Eros”), a leading global company in the Indian film entertainment industry, announced today that it will issue a press release to report its results for the fiscal second quarter 2015 before the market opens on Wednesday, November 12, 2014.
Sign-up for Eros International to Report Fiscal Second Quarter 2015 Results on November 12, 2014 investment picks
Essent Group Ltd.
Sign-up for Essent Group Ltd. Reports Third Quarter 2014 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G025643-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/5/11G025643/Etrion-Logo-295040277816.gif GENEVA, SWITZERLAND--(Marketwired - November 06, 2014) - Etrion Corporation ("Etrion" or the "Company") (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management's discussion and analysis ("MD&A") for the three and nine months ended September 30, 2014.
Sign-up for Etrion Releases Third Quarter 2014 Results investment picks
SOLANA BEACH, Calif., Nov.
Sign-up for Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that the enrollment target of 650 patients has been reached for METEOR, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor (TKI). Top-line efficacy and safety data from METEOR are now expected in the second quarter of 2015.
Sign-up for Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: EchoStar Reports Third Quarter 2014 Financial Results to Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent